Literature DB >> 8277499

Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.

A Azuma1, Y Nakajima, N Nishizono, N Minakawa, M Suzuki, K Hanaoka, T Kobayashi, M Tanaka, T Sasaki, A Matsuda.   

Abstract

Design, synthesis, and tumor cell growth inhibitory effects of 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl derivatives of cytosine (1i, CNDAC), thymine (6a), uracil (6c), and adenine (6d) have been described. The synthesis of the target compounds was achieved from the corresponding 2'-keto nucleosides 2a-d. Cyanohydrins of 2a-d were converted to thionocarbonates, which were deoxygenated to give the desired 2'-beta-cyano-2'-deoxy derivatives 5a-d, followed by deprotection to furnish the target nucleosides. Of these nucleosides, CNDAC was the most potent inhibitor of cell growth with an IC50 value of 0.53 microM against L1210 cells. In vitro cytotoxicity of CNDAC against human tumor cell lines was also examined; compared with that of 1-beta-D-arabinofuranosylcytosine (ara-C) and 5-fluorouracil (5-FU), CNDAC was more cytotoxic to several cell lines refractory to ara-C. The in vivo effect of CNDAC on M5076 mouse reticulum cell sarcoma was very strong; 99% tumor volume inhibition on day 20 was achieved when it was administrated orally on days 1, 4, 7, 10, 13, and 16 at a dose of 400 mg/kg/day, while 5'-deoxy-5-fluorouridine (5'-DFUR) and 5-FU caused only 50% inhibition at a dose of 500 mg/kg/day and 28% inhibition at a dose of 50 mg/kg/day, respectively, on the same schedule. These results indicated that CNDAC may have potential as a new antineoplastic agent with a broad antitumor spectrum.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8277499     DOI: 10.1021/jm00078a006

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer.

Authors:  Amir Mehrvarz Sarshekeh; Henry Q Xiong; Kenzo Iizuka; Howard S Hochster; Scott Kopetz
Journal:  Invest New Drugs       Date:  2018-06-13       Impact factor: 3.850

2.  CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death.

Authors:  Xiaojun Liu; Yingjun Jiang; Kei-Ichi Takata; Billie Nowak; Chaomei Liu; Richard D Wood; Walter N Hittelman; William Plunkett
Journal:  Mol Cancer Ther       Date:  2019-09-09       Impact factor: 6.261

3.  Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides.

Authors:  T Obata; Y Endo; M Tanaka; H Uchida; A Matsuda; T Sasaki
Journal:  Jpn J Cancer Res       Date:  2001-07

4.  Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine.

Authors:  Y Shimamoto; A Fujioka; H Kazuno; Y Murakami; H Ohshimo; T Kato; A Matsuda; T Sasaki; M Fukushima
Journal:  Jpn J Cancer Res       Date:  2001-03

Review 5.  The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold.

Authors:  Mary K Yates; Katherine L Seley-Radtke
Journal:  Antiviral Res       Date:  2018-12-08       Impact factor: 10.103

6.  Branched-chain C-cyano pyranonucleosides: synthesis of 3'-C-cyano & 3'-C-cyano-3'-deoxy pyrimidine pyranonucleosides as novel cytotoxic agents.

Authors:  Christos Kiritsis; Stella Manta; Vanessa Parmenopoulou; Jan Balzarini; Dimitri Komiotis
Journal:  Eur J Med Chem       Date:  2011-09-01       Impact factor: 6.514

7.  Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.

Authors:  M Serova; C M Galmarini; A Ghoul; K Benhadji; S R Green; J Chiao; S Faivre; E Cvitkovic; C Le Tourneau; F Calvo; E Raymond
Journal:  Br J Cancer       Date:  2007-07-17       Impact factor: 7.640

8.  Dideoxy fluoro-ketopyranosyl nucleosides as potent antiviral agents: synthesis and biological evaluation of 2,3- and 3,4-dideoxy-3-fluoro-4- and -2-keto-beta-d-glucopyranosyl derivatives of N(4)-benzoyl cytosine.

Authors:  Stella Manta; Evangelia Tsoukala; Niki Tzioumaki; Ales Goropevsek; Ravi Teja Pamulapati; Avrelija Cencic; Jan Balzarini; Dimitri Komiotis
Journal:  Eur J Med Chem       Date:  2009-01-29       Impact factor: 6.514

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.